KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbbVie (ABBV) Enterprise Value (2016 - 2026)

AbbVie has reported Enterprise Value over the past 14 years, most recently at -$5.2 billion for Q4 2025.

  • Quarterly Enterprise Value rose 5.46% to -$5.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.2 billion through Dec 2025, up 5.46% year-over-year, with the annual reading at -$5.2 billion for FY2025, 5.46% up from the prior year.
  • Enterprise Value was -$5.2 billion for Q4 2025 at AbbVie, up from -$5.6 billion in the prior quarter.
  • Over five years, Enterprise Value peaked at -$5.1 billion in Q1 2025 and troughed at -$18.0 billion in Q1 2024.
  • The 5-year median for Enterprise Value is -$9.0 billion (2022), against an average of -$9.3 billion.
  • Year-over-year, Enterprise Value skyrocketed 76.29% in 2021 and then plummeted 169.37% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$9.8 billion in 2021, then rose by 6.18% to -$9.2 billion in 2022, then tumbled by 38.96% to -$12.8 billion in 2023, then skyrocketed by 56.84% to -$5.5 billion in 2024, then increased by 5.46% to -$5.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Enterprise Value are -$5.2 billion (Q4 2025), -$5.6 billion (Q3 2025), and -$6.4 billion (Q2 2025).